Gilead Sciences (GILD) Q4 2025 adj. earnings decline, despite higher revenues
Gilead Sciences, Inc. (NASDAQ: GILD), a research-based biopharmaceutical company, has reported a decline in adjusted earnings for the fourth quarter...
ADVERTISEMENT
Healthcare
Key highlights from Humana’s (HUM) Q4 2025 earnings results
Humana Inc. (NYSE: HUM) reported its fourth quarter 2025 earnings results today. Total revenues were $32.5 billion compared to $29.2...
Quest Diagnostics Shares Jump on Q4 Beat; FY25 Revenue Rises, 2026 Outlook Raised
Shares, 52-Week Range, Recent Trend Quest Diagnostics Inc. (NYSE: DGX) shares rose sharply following its Q4 and FY 2025...
Medpace Q4 Earnings Beat Overshadowed by Cancellation Spike
Medpace Holdings, Inc. (NASDAQ: MEDP) delivered a strong fourth quarter with significant top-line and bottom-line growth, beating analyst estimates. However,...
InMode shares move after fourth-quarter revenue growth and full-year decline
InMode Ltd (NASDAQ: INMD) reported its financial results for the fourth quarter and full year ended December 31, 2025, showing...
Zimmer Biomet shares climb after fourth-quarter sales and earnings growth
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) closed at $93.60, up 4.3% on the day, after reporting fourth-quarter and full-year 2025...
Incyte Corporation Reports Strong 2025 Fiscal Results and Provides 2026 Guidance
Incyte achieved total revenue of $5.14 billion for the full year 2025, a 21% year-over-year increase driven by demand for...
CVS Health Reports Record 2025 Revenue of $402.1 Billion and Reaffirms 2026 Earnings Guidance
CVS Health Corporation (NYSE: CVS) reported record full-year 2025 consolidated revenues of $402.1 billion, a 7.8% increase over the prior...
CVS Health (CVS) Q4 2025 revenue rises 8%; adjusted earnings decline
Healthcare solutions company CVS Health Corporation (NYSE: CVS) on Monday reported an increase in revenues for the fourth quarter of...
Waters Corporation (WAT) Shares Fall 14.5% Following FY2026 Guidance Despite Q4 Beat
Waters Corporation (WAT) shares dropped 14.49% to $326.04 in early trading on Tuesday after the life sciences company issued 2026...